DP方案联合肿瘤抗血管生成药物在非小细胞肺癌治疗中的效果研究

Effect of DP scheme combined with tumor anti-angiogenic drugs on treatment of patients with non-small cell lung cancer

目的探讨DP方案联合肿瘤抗血管生成药物在非小细胞肺癌中的临床疗效。方法选取晚期非小细胞肺癌患者37例,按照是否使用抗肿瘤血管生成药物分为DP组和DP+YH16组。DP组采用多西紫杉醇+顺铂的化疗方案,DP+YH16组采用多西紫杉醇+顺铂+恩度的化疗方案。比较2组患者化疗2个周期后的临床疗效、生活质量改善情况、不良反应发生情况。结果 DP组患者治疗有效率为27.78%,临床收益率为72.22%;DP+YH16组患者治疗有效率为57.89%,临床收益率为94.73%。DP+YH16组的临床有效率以及临床受益率均显著优于DP组(P<0.05)。2组患者化疗期间的不良反应主要以造血系统以及肝功能损害为主,但差异无统计学意义(P>0.05)。DP+YH16组患者化疗结束后的生活质量较DP组有所改善,但差异无统计学意义(P>0.05)。结论 DP方案联合肿瘤抗血管生成药物治疗非小细胞肺癌,能有效提高临床治疗有效率以及受益率。

Objective To explore the effect of DP scheme combined with tumor anti-angiogentic drugs on treatment of patients with non-small cell lung cancer（ NSCLC）. Methods Thirtyseven patients with advanced NSCLC were selected and divided into DP group and DP ＋ YH16 group according to the use of anti-tumor angiogenesis drugs. DP group was treated with docetaxel plus cisplatin chemotherapy regimen,while DP ＋ YH16 group was treated with docetaxel plus cisplatin plus endostar chemotherapy. Clinical efficacy,the improvement of quality of life and adverse reactions after two cycles of chemotherapy were compared between the two groups. Results In the DP group,the effective rate was 27. 78%,and the clinical benefit rate was 72. 22%. In the DP ＋ YH16 group,the effective rate was 57. 89%,and the clinical benefit rate was 94. 73%. The clinical effective rate and clinical benefit rate of DP ＋ YH16 group were significantly better than DP group（ P〈0. 05）. The adverse reactions were mainly hematopoietic system and liver function damage in both groups,but there was no significant difference（ P〉0. 05）. The improvement of quality of life in DP ＋ YH16 group was better than DP group,but there was no significant difference（ P〈0. 05）. Conclusion DP regimen combined with anti-angiogentic drugs for patients with NSCLC can effectively improve the clinical effective rate and benefit rate.